Our results suggest that SET overexpression predicts poor outcome in elderly CRC patients and that this overexpression could also be predictive of a clinical benefit derived from the use of SET targeting therapies such as the PP2A activator FTY720 or specific SET antagonists [30,31,32,33,34]. The gene discussed is PTPA; the disease is colorectal carcinoma.